Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis

NCT04331795 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Tocilizumab
DRUG: Tocilizumab

Sponsor

University of Chicago